A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)

NCT03769116 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Muscular Dystrophy, Duchenne

Interventions

GENETIC: delandistrogene moxeparvovec
GENETIC: placebo

Sponsor

Sarepta Therapeutics, Inc.